Moreover, it might appear counterintuitive to explain the significantly clinical and radiological improvement of BM from NSCLC patients in terms of STAT3 inhibition because the suppressive effects of the silibinin-based nutraceutical Legasil® on progressive BM occurred without affecting the primary lung tumor outgrowth in NSCLC patients. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.